BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38652717)

  • 1. Lytic bacteriophages induce the secretion of antiviral and proinflammatory cytokines from human respiratory epithelial cells.
    Zamora PF; Reidy TG; Armbruster CR; Sun M; Van Tyne D; Turner PE; Koff JL; Bomberger JM
    PLoS Biol; 2024 Apr; 22(4):e3002566. PubMed ID: 38652717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lytic bacteriophages interact with respiratory epithelial cells and induce the secretion of antiviral and proinflammatory cytokines.
    Zamora PF; Reidy TG; Armbruster CR; Sun M; Van Tyne D; Turner PE; Koff JL; Bomberger JM
    bioRxiv; 2024 Feb; ():. PubMed ID: 38370761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of a Broad-Range Bacteriophage Cocktail That Reduces Pseudomonas aeruginosa Biofilms and Treats Acute Infections in Two Animal Models.
    Forti F; Roach DR; Cafora M; Pasini ME; Horner DS; Fiscarelli EV; Rossitto M; Cariani L; Briani F; Debarbieux L; Ghisotti D
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells.
    Alemayehu D; Casey PG; McAuliffe O; Guinane CM; Martin JG; Shanahan F; Coffey A; Ross RP; Hill C
    mBio; 2012; 3(2):e00029-12. PubMed ID: 22396480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of Bacteriophages in Removing Biofilms of
    Fong SA; Drilling A; Morales S; Cornet ME; Woodworth BA; Fokkens WJ; Psaltis AJ; Vreugde S; Wormald PJ
    Front Cell Infect Microbiol; 2017; 7():418. PubMed ID: 29018773
    [No Abstract]   [Full Text] [Related]  

  • 6. Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.
    Chang RYK; Das T; Manos J; Kutter E; Morales S; Chan HK
    AAPS J; 2019 Apr; 21(3):49. PubMed ID: 30949776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and Characterization of Three Pseudomonas aeruginosa Viruses with Therapeutic Potential.
    Wang X; Tang J; Dang W; Xie Z; Zhang F; Hao X; Sun S; Liu X; Luo Y; Li M; Gu Y; Wang Y; Chen Q; Shen X; Xu L
    Microbiol Spectr; 2023 Jun; 11(3):e0463622. PubMed ID: 37125933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.
    Olszak T; Zarnowiec P; Kaca W; Danis-Wlodarczyk K; Augustyniak D; Drevinek P; de Soyza A; McClean S; Drulis-Kawa Z
    Appl Microbiol Biotechnol; 2015 Jul; 99(14):6021-33. PubMed ID: 25758956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of Pseudomonas aeruginosa veterinary isolates to Pbunavirus PB1-like phages.
    Fujiki J; Furusawa T; Munby M; Kawaguchi C; Matsuda Y; Shiokura Y; Nakamura K; Nakamura T; Sasaki M; Usui M; Iwasaki T; Gondaira S; Higuchi H; Sawa H; Tamura Y; Iwano H
    Microbiol Immunol; 2020 Nov; 64(11):778-782. PubMed ID: 32918505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current knowledge in the use of bacteriophages to combat infections caused by Pseudomonas aeruginosa in cystic fibrosis.
    Martínez-Gallardo MJ; Villicaña C; Yocupicio-Monroy M; Alcaraz-Estrada SL; León-Félix J
    Folia Microbiol (Praha); 2023 Feb; 68(1):1-16. PubMed ID: 35931928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against
    Rossitto M; Fiscarelli EV; Rosati P
    Front Microbiol; 2018; 9():775. PubMed ID: 29780361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of phages and conditions for the safe phage therapy against Pseudomonas aeruginosa infections.
    Krylov V; Shaburova O; Pleteneva E; Krylov S; Kaplan A; Burkaltseva M; Polygach O; Chesnokova E
    Virol Sin; 2015 Feb; 30(1):33-44. PubMed ID: 25680443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways.
    Trend S; Fonceca AM; Ditcham WG; Kicic A; Cf A
    J Cyst Fibros; 2017 Nov; 16(6):663-670. PubMed ID: 28720345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phage Therapy Is Effective in a Mouse Model of Bacterial Equine Keratitis.
    Furusawa T; Iwano H; Hiyashimizu Y; Matsubara K; Higuchi H; Nagahata H; Niwa H; Katayama Y; Kinoshita Y; Hagiwara K; Iwasaki T; Tanji Y; Yokota H; Tamura Y
    Appl Environ Microbiol; 2016 Sep; 82(17):5332-9. PubMed ID: 27342558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice.
    Vinodkumar CS; Kalsurmath S; Neelagund YF
    Indian J Pathol Microbiol; 2008; 51(3):360-6. PubMed ID: 18723958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.
    Jault P; Leclerc T; Jennes S; Pirnay JP; Que YA; Resch G; Rousseau AF; Ravat F; Carsin H; Le Floch R; Schaal JV; Soler C; Fevre C; Arnaud I; Bretaudeau L; Gabard J
    Lancet Infect Dis; 2019 Jan; 19(1):35-45. PubMed ID: 30292481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lytic activity by temperate phages of Pseudomonas aeruginosa in long-term cystic fibrosis chronic lung infections.
    James CE; Davies EV; Fothergill JL; Walshaw MJ; Beale CM; Brockhurst MA; Winstanley C
    ISME J; 2015 Jun; 9(6):1391-8. PubMed ID: 25461970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacteriophages of Pseudomonas aeruginosa: long-term prospects for use in phage therapy.
    Krylov VN
    Adv Virus Res; 2014; 88():227-78. PubMed ID: 24373314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and impact on
    Forti F; Bertoli C; Cafora M; Gilardi S; Pistocchi A; Briani F
    Microbiol Spectr; 2023 Dec; 11(6):e0147723. PubMed ID: 37966242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A synthetic biology approach to assemble and reboot clinically relevant
    Ipoutcha T; Racharaks R; Huttelmaier S; Wilson CJ; Ozer EA; Hartmann EM
    Microbiol Spectr; 2024 Mar; 12(3):e0289723. PubMed ID: 38294230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.